Dec 17 (Reuters) – Eli Lilly is slashing the prices of its popular diabetes and weight-loss drugs Mounjaro and Zepbound by 20% or more in Canada, the Globe and Mail reported on Wednesday, citing a note to pharmacies issued by the U.S.-based drugmaker.
The Canadian list price of a four-week supply of Mounjaro or Zepbound would be lowered to 300 Canadian dollars ($217) for 2.5 mg and 5 mg doses, the report said.
Higher 7.5 and 10 mg doses will cost 420 Canadian dollars for a four-week supply, the report said, adding that the new prices take effect on December 29.
Eli Lilly did not immediately respond to a request for comment outside regular business hours. Reuters could not immediately verify the report.
Earlier in December, Eli Lilly lowered the price of single-dose vials of its obesity drug Zepbound to make the treatment more affordable for U.S. patients.
($1 = 1.3783 Canadian dollars)
(Reporting by Anusha Shah in Bengaluru; Editing by Mrigank Dhaniwala)